Resistant hypertension: Patient characteristics, risk factors, co-morbidities and outcomes

Journal of Human Hypertension

Volumn 28, Issue 4, 2014, Pages 213-217

  Oliveras, A ^a   De La Sierra, A ^b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ambulatory blood pressure monitoring; cardiovascular prognosis; resistant hypertension

Indexed keywords

ALBUMINURIA; BLOOD PRESSURE MONITORING; CLINICAL EVALUATION; CLINICAL FEATURE; DIABETES MELLITUS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INCIDENCE; MEDICAL HISTORY; MORBIDITY; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; PROGNOSIS; RESISTANT HYPERTENSION; REVIEW; RISK FACTOR; TARGET ORGAN; TUNICA ALBUGINEA; AGED; COMPLICATION; DRUG RESISTANCE; FEMALE; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENT;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DIABETES COMPLICATIONS; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896318356     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.77     Document Type: Review

References (36)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment-a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419.
2. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357.
3. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898-902.
4. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14: 7-12.
5. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57: 1076-1080.
6. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642.
7. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens 2001; 14: 1263-1269.
8. Cuspidi C, Sala C, Valerio C, Negri F, Mancia G. Nocturnal hypertension and organ damage in dippers and nondippers. Am J Hypertens 2012; 25: 869-875.
9. Oliveras A, Armario P, Martell N, Ruilope LM, de la Sierra A. Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. Hypertension 2011; 57: 556-560.
10. Muxfeldt ES, Salles GF. How to use ambulatory blood pressure monitoring in resistant hypertension. Hypertens Res 2013; 36: 385-389.
11. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. True resistant hypertension: is it possible to be recognized in the office? Am J Hypertens 2005; 18: 1534-1540.
12. de la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 2012; 30: 1211-1216.
13. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18: 1422-1428.
14. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension. A prospective study. Hypertension 1998; 31: 712-718.
15. Salles GF, Cardoso CRL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008; 168: 2340-2346.
16. De la Sierra A. Profile of ambulatory blood pressure in resistant hypertension. Hypertens Res 2013; 36(7): 565-569.
17. Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008; 51: 69-76.
18. Muxfeldt ES, Fiszman R, de Souza F, Viegas B, Oliveira FC, Salles GF. Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. Hypertension 2012; 59: 384-389.
19. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124: 1046-1058.
20. Oliveras A, Armario P, Hernández-del Rey R, Arroyo JA, Poch E, Larrousse M et al. Urinary albumin excretion is associated with true resistant hypertension. J Hum Hypertens 2010; 24: 27-33.
21. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyper-aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.
22. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22: 2217-2226.
23. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volumen expansion. Arch Intern Med 2008; 168: 1159-1164.
24. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-845.
25. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55: 147-152.
26. Václav́ik J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J et al. Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT). A randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075.
27. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; 28: 2329-2335.
28. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A et al. Human adipocytes secrete mineralocorticoid- releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-14216.
29. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010; 6: 363-368.
30. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58: 811-817.
31. Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B et al. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest 2013; 143: 978-983.
32. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6: 152-158.
33. Symplicity HTN-1Investigators. Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917.
34. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
35. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063-2070.
36. De la Sierra A, Larrousse M, Oliveras A, Armario P, Hernández del Rey R, Poch E et al. Abnormalities of vascular function in resistant hypertension. Blood Press 2012; 21: 104-109.